Cure8 research brief
This trial tested a new monoclonal antibody directed at TLR3 in moderate-to-severe ulcerative colitis to see if it is safe and biologically active.
While PRV-300 showed some target engagement in colon biopsies, it did not improve clinical or endoscopic measures in this study, which is important for future research directions.
Clinicians, IBD researchers, patients with ulcerative colitis interested in emerging biologic treatments, and those following early-phase trial developments.
The study randomized 38 patients to intravenous PRV-300 or placebo with 12 weeks of treatment and 8 weeks of follow-up. The primary goal was safety and tolerability; PRV-300 was generally tolerated with most adverse events described as mild and only two discontinuations related to adverse events.
Although biopsies showed some evidence that PRV-300 reduced TLR3 expression (target engagement), this did not lead to improvement in clinical scores or endoscopic severity versus placebo in this trial. The authors conclude that blocking TLR3 did not produce a clear clinical benefit in this study population.
Phase 1b trials are primarily designed to evaluate safety and pharmacodynamics in small groups. Lack of clinical benefit here does not fully rule out the mechanism but suggests it may not be a pivotal driver of disease for the enrolled population or that different approaches would be required.
Review the original publication for the complete reporting, methods, and context.
Funding disclosed by the source: Provention Bio
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Early-phase trials test safety and tolerability of new mechanisms; this study evaluates an anti–IL-18 antibody (aletekitug) which could represent a different therapeutic approach for people with moderate-to-severe UC if...
A new oral investigational drug (HRS-7085) is entering early human testing for moderate-to-severe ulcerative colitis. People with UC who have not benefited from approved therapies may be interested in trial options and...
This report describes early human evidence that an oral, gut-targeted PDE4 inhibitor (PALI-2108) may reduce intestinal inflammation and improve endoscopic findings in people with Crohn's disease and ulcerative colitis —...
